If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 85K)  | Related Articles | Citation Tracking

Double Filtration Plasmapheresis in Critical Care
Michio Mineshima and Takashi Akiba
  Division of Blood Purification, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan
Address correspondence and reprint requests to Dr. Michio Mineshima, Division of Blood Purification, Kidney Center, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. E-mail: mmine@kc.twmu.ac.jp
Copyright 2002 International Society for Apheresis
KEYWORDS
Double filtration plasmapheresis • Continuous monitoring of blood volume • Plasma fractionator • Albumin solution

ABSTRACT

Abstract:Many kinds of technologies have been introduced and successfully developed for therapeutic apheresis. Furthermore, several kinds of these technologies have also been applied in critical care. Double filtration plasmapheresis (DFPP), however, is rarely applied in this field in comparison with other treatments such as continuous hemofiltration, continuous hemodiafiltration, single filtration plasmapheresis, and plasma adsorption therapies. In this paper, the characteristics of the DFPP treatments for critical care are summarized. During the DFPP treatments, the patient's blood volume (BV) often decreases with time due to albumin loss induced by inadequate albumin infusion in a supplementation fluid. We examined the change of BV by a continuous hematocrit monitor, Crit-Line, during an in vivo study for 9 patients. As a result, albumin loss fairly occurred in DFPP treatments. The decrease of patient BV was induced by an oncotic pressure drop due to albumin loss and often resulted in a blood pressure drop. This is a serious problem for DFPP in critical care. We should avoid inadequate albumin infusion if the patient is suffering from these adverse effects. In order to determine the optimal concentration CS and volume VS values of a supplemented albumin solution, we introduced a variable blood volume model for albumin transport in DFPP.


Received March 2002.

DIGITAL OBJECT IDENTIFIER (DOI)
10.1046/j.1526-0968.2002.00428.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member